WASHINGTON (Legal Newsline) — The U.S. Department of Justice announced April 9 that Biotheranostics Inc. will pay $2 million after allegedly submitting false claims to Medicare for Breast Cancer Index (BCI) tests that were not necessary.

“Health care providers are responsible for ensuring that the services they provide to Medicare beneficiaries are both reasonable and necessary,” Chad A. Readler, acting assistant attorney general of the Justice Department’s Civil Division, said in a statement. “Laboratories that knowingly submit claims for non-reimbursable services will be held accountable. 

The Justice Department alleges Biotheranostics ignored published clinical trial data and clinical practice guidelines when it gave BCI tests to breast cancer patients. These patients had not been in remission for five years and were not taking tamoxifen as the data and guidelines mandated. Therefore, Biotheranostic violated federal law when it billed Medicare for those tests.

“Fighting health care fraud will continue to be a priority of this office,” U.S. attorney Adam L. Braverman for the Southern District of California, said in a statement. “As this settlement demonstrates, we will vigorously investigate and hold responsible laboratories and other providers that choose to submit claims to federal health care programs for unauthorized or unnecessary services.”

Alerts Sign-up

Want to get notified whenever we write about U.S. Department of Justice ?
Next time we write about U.S. Department of Justice, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

By signing up for alerts, you agree to the privacy policy & terms of service.

Organizations in this Story

U.S. Department of Justice

More News